Seminars in Colon & Rectal Surgery
Volume 17, Issue 4 , Pages 171-176 , December 2006

Effect of Sulindac on Gene Expression in Rectal MucosaLimited Project Grant #071

References 

  1. Sporn MB, Dunlop NM, Newton DL, et al. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc. 1976;35:1332–1338
  2. Puig-La Calle J, Guillem JG. Genetics, screening, and chemoprevention. In:  Audisio RA,  Geraghty JG,  Longo WE editor. Modern Management of Cancer of the Rectum. London: Springer-Verlag; 2001;p. 21–31
  3. Thun MJ, Namboodiri MM, Heath CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991;325:1593–1596
  4. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science. 1990;247:322–324
  5. Boolbol SK, Dannenberg AJ, Chadburn A, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 1996;56:2556–2560
  6. Beazer-Barclay Y, Levy DB, Moser AR, et al. Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis. 1996;17:1757–1760
  7. Jacoby RF, Marshall DJ, Newton MA, et al. Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res. 1996;56:710–714
  8. Kawamori T, Rao CV, Seibert K, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 1998;58:409–412
  9. Reddy BS, Rao CV, Rivenson A, et al. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis. 1993;14:1493–1497
  10. Oshima M, Murai N, Kargman S, et al. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res. 2001;61:1733–1740
  11. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993;328:1313–1316
  12. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342:1946–1952
  13. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med. 1993;122:518–523
  14. Yuan CJ, Mandal AK, Zhang Z, et al. Transcriptional regulation of cyclooxygenase-2 gene expression: novel effects of nonsteroidal anti-inflammatory drugs. Cancer Res. 2000;60:1084–1091
  15. Taylor MT, Lawson KR, Ignatenko NA, et al. Sulindac sulfone inhibits K-ras-dependent cyclooxygenase-2 expression in human colon cancer cells. Cancer Res. 2000;60:6607–6610
  16. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 1996;87:803–809
  17. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995;83:493–501
  18. Nugent KP, Farmer KC, Spigelman AD, et al. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg. 1993;80:1618–1619
  19. Yang VW, Geiman DE, Hubbard WC, et al. Tissue prostanoids as biomarkers for chemoprevention of colorectal neoplasia: correlation between prostanoid synthesis and clinical response in familial adenomatous polyposis. Prostaglandins Other Lipid Mediat. 2000;60:83–96
  20. Yang W, Velcich A, Mariadason J, et al. p21(WAF1/cip1) is an important determinant of intestinal cell response to sulindac in vitro and in vivo. Cancer Res. 2001;61:6297–6302
  21. Giardiello FM, Yang VW, Hylind LM, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med. 2002;346:1054–1059
  22. Howe LR, Subbaramaiah K, Chung WJ, et al. Transcriptional activation of cyclooxygenase-2 in Wnt-1-transformed mouse mammary epithelial cells. Cancer Res. 1999;59:1572–1577
  23. Vogiagis D, Brown W, Glare EM, et al. Rat colorectal tumours treated with a range of non-steroidal anti-inflammatory drugs show altered cyclooxygenase-2 and cyclooxygenase-1 splice variant mRNA expression levels. Carcinogenesis. 2001;22:869–874
  24. Keller JJ, Offerhaus GJ, Drillenburg P, et al. Molecular analysis of sulindac-resistant adenomas in familial adenomatous polyposis. Clin Cancer Res. 2001;7:4000–4007
  25. Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology. 1991;101:635–639
  26. Whelan J, Chiu CH, McEntee MF. Intestinal tumor load in the Min/+ mouse model is not correlated with eicosanoid biosynthesis. Adv Exp Med Biol. 1999;469:607–615
  27. Charalambous D, Skinner SA, O’Brien PE. Sulindac inhibits colorectal tumour growth, but not prostaglandin synthesis in the rat. J Gastroenterol Hepatol. 1998;13:1195–1200
  28. Soh JW, Mao Y, Kim MG, et al. Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase 1. Clin Cancer Res. 2000;6:4136–4141
  29. Piazza GA, Rahm AL, Krutzsch M, et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res. 1995;55:3110–3116
  30. Chan TA, Morin PJ, Vogelstein B, et al. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA. 1998;95:681–686
  31. Hanif R, Pittas A, Feng Y, et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol. 1996;52:237–245
  32. Shureiqi I, Chen D, Lotan R, et al. 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res. 2000;60:6846–6850
  33. Rice PL, Goldberg RJ, Ray EC, et al. Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites. Cancer Res. 2001;61:1541–1547
  34. Shiff SJ, Qiao L, Tsai LL, et al. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest. 1995;96:491–503
  35. Yang W, Bancroft L, Augenlicht LH. Methylation in the p21WAF1/cip1 promoter of Apc+/−, p21+/− mice and lack of response to sulindac. Oncogene. 2005;24:2104–2109
  36. Yang W, Bancroft L, Liang J, et al. p27kip1 in intestinal tumorigenesis and chemoprevention in the mouse. Cancer Res. 2005;65:9363–9368
  37. Koornstra JJ, Rijcken FE, Oldenhuis CN, et al. Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev. 2005;14:1608–1612
  38. Boon EM, Keller JJ, Wormhoudt TA, et al. Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer. 2004;90:224–229
  39. Thompson WJ, Piazza GA, Li H, et al. Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000;60:3338–3342
  40. Bordonaro M, Mariadason JM, Aslam F, et al. Butyrate-induced apoptotic cascade in colonic carcinoma cells: modulation of the beta-catenin-Tcf pathway and concordance with effects of sulindac and trichostatin A but not curcumin. Cell Growth Differ. 1999;10:713–720
  41. Zhang Z, DuBois RN. Par-4, a proapoptotic gene, is regulated by NSAIDs in human colon carcinoma cells. Gastroenterology. 2000;118:1012–1017
  42. Richter M, Weiss M, Weinberger I, et al. Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors. Carcinogenesis. 2001;22:17–25
  43. Zhang T, Fields JZ, Ehrlich SM, et al. The chemopreventive agent sulindac attenuates expression of the antiapoptotic protein survivin in colorectal carcinoma cells. J Pharmacol Exp Ther. 2004;308:434–437
  44. Qiao L, Shiff SJ, Rigas B. Sulindac sulfide alters the expression of cyclin proteins in HT-29 colon adenocarcinoma cells. Int J Cancer. 1998;76:99–104
  45. Notterman DA, Alon U, Sierk AJ, et al. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res. 2001;61:3124–3130
  46. Harrington C, Rosenow C, Retief J. Monitoring gene expression using DNA microarrays. Curr Opin Microbiol. 2000;3:285–291
  47. Augenlicht LH, Velcich A, Klampfer L, et al. Application of gene expression profiling to colon cell maturation, transformation and chemoprevention. J Nutr. 2003;133:2410S–2416S
  48. Alon U, Barkai N, Notterman DA, et al. Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc Natl Acad Sci USA. 1999;96:6745–6750
  49. Eisen MB, Spellman PT, Brown PO, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA. 1998;95:14863–14868
  50. Mariadason JM, Corner GA, Augenlicht LH. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res. 2000;60:4561–4572
  51. Akashi H, Han HJ, Iizaka M, et al. Growth-suppressive effect of non-steroidal anti-inflammatory drugs on 11 colon-cancer cell lines and fluorescence differential display of genes whose expression is influenced by sulindac. Int J Cancer. 2000;88:873–880
  52. Finan PJ, Ritchie JK, Hawley PR. Synchronous and ‘early’ metachronous carcinomas of the colon and rectum. Br J Surg. 1987;74:945–947
  53. Maxfield RG. Colonoscopy as a routine preoperative procedure for carcinoma of the colon. Am J Surg. 1984;147:477–480
  54. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106–130

 Supported by Limited Project Grant 071 “Effect of Sulindac on Gene Expression in Rectal Mucosa,” awarded to H.G.M. by the Research Foundation of the American Society of Colon and Rectal Surgeons.

PII: S1043-1489(06)00089-3

doi: 10.1053/j.scrs.2006.10.005

Seminars in Colon & Rectal Surgery
Volume 17, Issue 4 , Pages 171-176 , December 2006

Article Tools

* Image Usage & Resolution